InsiderFinancial

$RAD Looking To Reverse The Downtrend

Long
NYSE:RAD   None
$RAD is showing signs of bullishness after breaking out to the upside above $11. With the charts showing an inverse head and shoulders pattern, we believe the worse is over for $RAD. Shares are also now trading above the 200 day moving average of $9.76 a share.

Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment sells prescription drugs and an assortment of other merchandise, including over-the-counter medications, health and beauty aids, personal care items, cosmetics, household items, food and beverages, greeting cards, seasonal merchandise, and other every day and convenience products. It also operates retail clinics that provide treatment for common conditions; and provides preventative services, such as screenings, medical tests, immunizations, and basic physical exams. In addition, this segment offers healthcare coaching and disease management services. The Pharmacy Services segment provides pharmacy benefit management (PBM) services and a range of pharmacy-related services. This segment also performs prescription adjudication services for other PBMs; and offers integrated mail-order and specialty pharmacy services, as well as drug benefits under the federal government's Medicare Part D program. As of April 11, 2019, the company operated 2,469 stores in 18 states. Rite Aid Corporation was founded in 1927 and is headquartered in Camp Hill, Pennsylvania.

As always, trade with caution and use protective stops.

Good luck to all!
Trade active:
Took some patience, but subscribers now up 62% in $RAD!

To receive our alerts via email and SMS, join Insider Financial for Free at signup.insiderfinancial.com

We are not financial advisors. Always conduct your own research and read our full disclaimer at insiderfinancial.com/disclaimer/
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.